News from Target Ovarian Cancer

Professor Sir Kenneth Calman, Patron of Target Ovarian Cancer, seated

08.02.10A meeting of minds Ovarian Cancer Research Meeting, London, February 2010.

Leading ovarian cancer researchers, funders and patient groups met at the Royal College of Obstetricians and Gynaecologists in London on February 11th to review the current position in ovarian cancer research and to explore opportunities to build on recent advances in diagnosis, treatment and research into new therapies with the ultimate objective of improving survival and quality of life for women with ovarian cancer. 


Chaired by Professor Sir Kenneth Calman, the meeting brought together, for the first time, a broad range of specialists from across the UK to tackle the key issues in ovarian cancer and discuss the way forward. Professor Ate Van der Zee, President of the European Society of Gynaecological Oncology, and Professor Mike Birrer, Director of Gynaecological Oncology at Harvard Medical School, attended as expert international commentators. Leading charities with an interest in ovarian cancer research - Target Ovarian Cancer, Cancer Research UK, The Eve Appeal, Ovacome and Wellbeing of Women – also participated in the deliberations.


Speakers included:


  • Dr James Brenton, University of Cambridge
  • Professor Hilary Calvert, University College London
  • Dr Jane Cope, Director, National Cancer Research Institute
  • Professor Gordon Jayson, University of Manchester
  • Annwen Jones, Chief Executive, Target Ovarian Cancer
  • Professor Henry Kitchener, University of Manchester
  • Professor Jonathan Ledermann, University College London; National Cancer Research Institute Gynaecological Cancer Clinical Studies Group
  • Professor Usha Menon, University College London
  • Frances Reid, Director of Public Affairs, Target Ovarian Cancer


Annwen Jones, Chief Executive of Target Ovarian Cancer, comments “We are all committed to understanding how we can diagnose ovarian cancer more quickly and how we can deliver more treatment choices more quickly, particularly for women with recurrent disease. I look forward to continuing this vital dialogue with others and to working in collaboration to achieve these goals”.


A summary of the meeting’s proceedings will be published.


Professor Sir Kenneth Calman is Chairman of the National Cancer Research Institute, and Patron of Target Ovarian Cancer who supported the organisation of this meeting.